%PDF-1.4
%
44 0 obj
<>
endobj
41 0 obj
<>
endobj
97 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-30T09:04:10Z
2024-03-28T16:25:19-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T16:25:19-07:00
application/pdf
Heather
2002-929.sept
uuid:f5b920a8-1dd1-11b2-0a00-7a08278d5b00
uuid:f5b920aa-1dd1-11b2-0a00-1e0000000000
endstream
endobj
30 0 obj
<>
endobj
31 0 obj
<>
endobj
45 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 18 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
111 0 obj
[115 0 R]
endobj
112 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(arthritis: a case of historical reasoning. Lancet 1999;354:1026-7.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Kerr JR. Pathogenesis of human parvovirus B19 in rheumatic)]TJ
0 Tc 1.675 -1.25 Td
[(disease. )54.9 (Ann Rheum Dis 2000;59:1)36.9 (153-6.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (White DG, )17.7 (W)79.9 (oolf )54.8 (AD, Mortimer PP)110.7 (, Cohen BJ, Blake DR, Bacon)]TJ
1.675 -1.25 Td
[(P)91.8 (A. Human parvovirus arthropathy)64.8 (. Lancet 1985;23:419-21.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Lunardi C, )17.7 (T)35 (iso M, Bor)17.7 (gato L, et al. Chronic parvovirus B19 )]TJ
1.675 -1.25 Td
(infection induces the production of antibodies with autoantigen)Tj
0 -1.25 TD
(binding properties. Eur J Immunol 1998;28:936-48.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Soderlund M, )17.7 (V)128.9 (on Essen R, J )54.8 (Arkko H, Urlo K, Kiviluoto O, Klaus)]TJ
1.675 -1.25 Td
[(H. Persistence of parvovirus B19 DNA)-220.2 (in synovial membranes of)]TJ
T*
[(young patients with and without chronic arthropathy)64.8 (. Lancet)]TJ
0 Tc 0 Tw T*
(1997;349:1063-5.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Murai C, Munakana )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (akahashi )36.8 (Y)128.9 (, et al. Rheumatoid arthritis after)]TJ
1.675 -1.25 Td
[(human parvovirus B19 infection. )54.8 (Ann Rheum Dis 1999;59:130-2.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (T)69.9 (akahashi )36.8 (Y)128.9 (, Murai C, Shibata S, et al. Human parvovirus B19 as a)]TJ
1.675 -1.25 Td
[(causative agent for rheumatoid arthritis. Proc Natl )54.8 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1998;95:8227-32.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Kerr JR, Cartron JP)110.7 (, Curran MD, Moore JE, Elliot JRM, Mollan)]TJ
2.175 -1.25 Td
[(RA. )54.8 (A)-220.1 (study of the role of parvovirus B19 in rheumatoid arthritis.)]TJ
T*
(Br J Rheumatol 1995;34:809-13.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Nikkari S, Roivainen )54.8 (A, Hamonen P)110.8 (, et al. Persistence of)]TJ
2.1381 -1.25 Td
[(parvovirus B19 in synovial tissue and bone marrow)64.8 (. )54.8 (Ann Rheum)]TJ
0 Tc T*
(Dis 1995;54:597-600.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Ozawa K, )36.8 (Y)99.8 (oung NS. Characterisation of capsid and noncapsid)]TJ
2.175 -1.25 Td
(proteins of B19 parvovirus propagated in human erythroid bone)Tj
T*
[(marrow cell cultures. J )17.7 (V)59.8 (irol 1987;61:2627-30.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Sol N, Junter JLE, )17.7 (V)110.8 (assias I, et al. Possible interaction between the)]TJ
2.175 -1.25 Td
(NS1 protein and tumor necrosis factor alpha pathways in erythroid)Tj
T*
[(cell apoptosis induced by parvovirus B19. J )17.7 (V)59.8 (irol 1999;73:8762-70.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Mof)17.7 (fatt S, )17.7 (T)69.9 (anaka N, )17.7 (T)69.9 (ada K. )54.8 (A)-220.1 (cytotoxic nonstructural protein,)]TJ
2.175 -1.25 Td
(NS1, of parvovirus B19 induces activation of interleukin 6 gene)Tj
T*
[(expression. J )17.7 (V)59.8 (irol 1996;70:8485-91.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (V)128.9 (on Poblotzki )54.8 (A, Hemauer )54.8 (A, Gigler )54.8 (A, et al. )54.8 (Antibodies to)]TJ
2.175 -1.25 Td
(nonstructural protein of parvovirus B19 in persistently infected)Tj
T*
(patients: implication for pathogenesis. J Infect Dis )Tj
0 Tc 0 Tw T*
(1995;172:1356-9.)Tj
-0.00011 Tc 0.02499 Tw 30.825 43.75 Td
[(16.)-875.1 (Kerr JR, Cannif)17.7 (fe )17.7 (VS. )54.8 (Antibodies to parvovirus B19 nonstructural)]TJ
2.175 -1.25 Td
(protein are associated with chronic but non acute arthritis following)Tj
T*
(B19 infection. Rheumatology 2000;39:903-8.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Chevrel G, Calvet )54.8 (A, Belin )17.7 (V)128.9 (, Miossec P)110.8 (. Dermatomyositis )]TJ
2.175 -1.25 Td
[(associated with the presence of parvovirus B19 DNA)-220.2 (in muscle.)]TJ
0 Tc T*
(Rheumatology 2000;39:1037-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Musiani M, )54.8 (Azzi )54.8 (A, Zerbini M, et al. Nested polymerase chain)]TJ
2.175 -1.25 Td
[(reaction assay for detection of B19 parvovirus DNA)-220.2 (in human)]TJ
T*
[(immunodeficiency virus patients. J Med )17.7 (V)59.8 (irol 1993;40:157-60.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Cope )54.8 (AP)110.8 (, Jones )54.8 (A, Brozovic M, Shafi MS, Maini RM. Possible)]TJ
2.175 -1.25 Td
(induction of systemic lupus erythematosus by human parvovirus.)Tj
0 Tc T*
(Ann Rheum Dis 1992;51:803-4.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875.1 (Ferri C, Zakrzewka K, Longobardo G, et al. Parvovirus B19 )]TJ
2.175 -1.25 Td
(infection of bone marrow in systemic sclerosis patients. Clin Exp)Tj
T*
(Rheumatol 1999;17:718-20.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Nikkari S, )17.7 (V)110.8 (ainionpaa R, )17.7 (T)69.9 (oivanen P)110.8 (.)-0.1 ( )54.8 (Association of )17.7 (W)79.9 (egener)-37 (\325)55.1 (s)]TJ
2.175 -1.25 Td
[(granulomatosis with parvovirus B19 infection. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
[(1995;38:1)36.9 (175-6.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Hokynar K, Brunstein J, Soderlund-V)110.7 (enermo M, et al. Integrity and)]TJ
2.175 -1.25 Td
[(full coding sequence of B19 virus DNA)-220.2 (persisting in human)]TJ
T*
[(synovial tissue. J Gen )17.7 (V)59.8 (irol 2000;81:1017-25.)]TJ
-2.175 -1.25 Td
[(24.)-875.1 (Nikkari S, )17.7 (V)128.9 (ourinen )17.7 (T)74 (, Kotilainen P)110.7 (, Lummintausta K. Presence of)]TJ
2.175 -1.25 Td
[(parvovirus B19 DNA)-220.2 (in the skin of healthy individuals. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42:338-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(25.)-875.1 (Loizou S, Cazabon JK, )17.7 (W)79.9 (alport MJ, )17.7 (T)69.9 (ait D, So )54.8 (AK. Similarities of)]TJ
2.175 -1.25 Td
(specificity and cofactor dependence in serum antiphospholipid )Tj
T*
(antibodies from patients with parvovirus B19 infection and from)Tj
T*
[(those with systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1997;40:103-8.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:9)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1910)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
24 0 obj
<>stream
8;Z\7$Zta&Yl0%<9:'I`KXXuV63(Lc_(M_j
,9O6:Z/j+"1s(6Bfp!h;abVQ8Rp(M8hW[^8:i[S?*KWEs5504>W4@!e8eXe0mAtDq
+u+A0M?Fr7B254U5NE("ol?G8c(\KFUXL)PbY>r="1O&ERfqkk0Tq6uUGFqgkg49&
W?AcpSejl2Xb+,&YHE/.kU$In=F,[\pMB)D?'M:TT&KTPV6sc+CcQ<2?+'0>jOdO\>nA
ZtGH3B7Y1C#L6o:M5.,lI7b2LgGK/;'/?'1kQl0,30i9:$S3%@9`dp\*\TOVoB4/2
aF<)!pY+pk9JSePet&QD61`F%@^sCGTYAjQ9qemj>mpBnLf[dYC9L9,k%o)5@30g;
3bDnHe#"W3DiKEO?2[?3$\^p@:ad"bKn@1Eita"\4Pn'FRe?2'))%6IZLTHY"ots(/X?~>
endstream
endobj
28 0 obj
[/Indexed/DeviceRGB 255 27 0 R]
endobj
27 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
52 0 obj
<>
endobj
47 0 obj
<>
endobj
88 0 obj
<>
endobj
102 0 obj
<>
endobj
48 0 obj
<>
endobj
83 0 obj
<>stream
HUiPSY~(C HH#ӠӖ ,J#H(!%M6 ("UQA[vFFeDZF֙җhϟ?S[sNw.YZ`8oo X([K':>c,`\YKٰ.*גp&$1Gڈ\Tr9гdS'+{<<>v&IPHE1rzձooߣ@FKL.]$4R.vi߸8WFK24P1-ё\-GJOҒ㴿(^"W$itd|:y((Z) e惱1lfc-!el5[om%=Xa